Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sunshine Biopharma (SBFM) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Sunshine Biopharma (SBFM) over the last 14 years, with Q3 2025 value amounting to 0.77.

  • Sunshine Biopharma's Equity Ratio fell 774.54% to 0.77 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.77, marking a year-over-year decrease of 774.54%. This contributed to the annual value of 0.77 for FY2024, which is 83.8% down from last year.
  • Latest data reveals that Sunshine Biopharma reported Equity Ratio of 0.77 as of Q3 2025, which was down 774.54% from 0.8 recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's Equity Ratio ranged from a high of 1.0 in Q2 2022 and a low of 0.58 during Q1 2021
  • Its 5-year average for Equity Ratio is 0.57, with a median of 0.78 in 2025.
  • As far as peak fluctuations go, Sunshine Biopharma's Equity Ratio surged by 66970.33% in 2022, and later plummeted by 2750.1% in 2023.
  • Quarter analysis of 5 years shows Sunshine Biopharma's Equity Ratio stood at 0.1 in 2021, then skyrocketed by 669.7% to 0.74 in 2022, then grew by 4.86% to 0.78 in 2023, then fell by 0.84% to 0.77 in 2024, then dropped by 0.06% to 0.77 in 2025.
  • Its Equity Ratio was 0.77 in Q3 2025, compared to 0.8 in Q2 2025 and 0.78 in Q1 2025.